Preslava Mihaylova Hristova

Prof. Preslava Mihaylova Hristova


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AAAlexandra Alexandrova
Alexandra Alexandrova
Vasil S. BoyanovVasil S. Boyanov
Vasil S. Boyanov
KMKalina Mihova
Kalina Mihova
PHPreslava Mihaylova Hristova
Preslava Mihaylova Hristova
HHHristina Y. Hitkova
Hristina Y. Hitkova
RGRaina Tzvetanova Gergova
Raina Tzvetanova Gergova
Streptococcus pneumoniae has been a PCV10 vaccine-preventable agent in Bulgaria since 2010. Our objective is to determine the phylogenetic structure of 170 invasive and non-invasive pneumococcal isolates, focusing on their serotypes and antimicrobial susceptibility. Serotyping was performed using latex agglutination, capsular swelling reaction, and serotype-specific PCRs. Antibiotic susceptibilities were assessed by broth microdilution. MLST was conducted to define the clonal composition. The non-PCV10 serotypes accounted for 88.2%. The predominant invasive pneumococcal disease (IPD) serotypes were 19A (39.3%), 19F (21.4%), 6C (10.7%), 7F (7.1%), and 3 (7.1%). The prevalent NIPD serotypes were 19A (18.3%), 6C (15.5%), 3 (10.6%), 15A (7.7%), and 6A (6.3%). The overall antimicrobial non-susceptibility rates were: benzylpenicillin (55.2%), ceftriaxone (15.2%), cefuroxime (35.8%), amoxicillin-clavulanic acid (38.8%), erythromycin (60.5%), clindamycin (57.0%), tetracycline (43.5%), trimethoprim-sulfamethoxazole (62.9%), and chloramphenicol (13.5%). The multidrug resistance (MDR) strains were 60.5%. The predominant clone CC320, represented 20.0% MDR 19A and 19F strains linked to Taiwan19F-14 and GPSC1. CC273/Greece6B-22 and CC386 accounted for 5.3% 6A and 6C isolates. Most serotype 3 isolates are associated with CC505, associated with Netherlands3-31 and GPSC12. Switching to a conjugate vaccine with broader serotype coverage could reduce the incidence of 19A, 6C, and 15A MDR S. pneumoniae clones in our country.

24 July 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
Teodora Vasileva Marinova-BulgaranovaTeodora Vasileva Marinova-Bulgaranova
Teodora Vasileva Marinova-Bulgaranova
PHPreslava Mihaylova Hristova
Preslava Mihaylova Hristova
PMPolya Marinovska
Polya Marinovska
NBNikolay Balgaranov
Nikolay Balgaranov
VNVladislav Nankov
Vladislav Nankov
HHHristina Hitkova
Hristina Hitkova
Acinetobacter baumannii is a formidable nosocomial pathogen responsible for severe hospital-acquired infections. This study aimed to investigate the relationship between genotypic and phenotypic resistance profiles in 36 non-duplicate invasive A. baumannii isolates collected at a tertiary care hospital in Bulgaria over a six-year period (2019–2024). Identification was performed by MALDI-TOF MS and PCR-based detection of blaOXA-51-like and gyrB. Antimicrobial susceptibility testing to ten agents was performed by gradient diffusion and broth microdilution, and selected resistance genes were detected by conventional PCR. Whole-genome sequencing of 17 representative isolates was conducted to confirm the resistance genotype–phenotype associations and perform MLST. Carbapenem resistance was detected in 34/36 isolates (94.4%), mediated by blaOXA-23-like (29/34) or blaOXA-72 (5/34). The armA gene associated with high-level resistance to all three aminoglycosides was identified exclusively in blaOXA-23-like-positive isolates (18/29). In armA-negative isolates, gentamicin and tobramycin MICs decreased markedly, whereas amikacin MICs remained elevated. In addition, minocycline MICs ≥ 8 mg/L were observed in the presence of armA. Seven distinct genotypic–phenotypic profiles were defined based on these gene–MIC associations. Resistome and phylogenetic analyses confirmed these relationships, with MLST assigning the isolates to established clonal lineages ST2 and ST636 (International Clone II). These findings support the use of targeted genes, such as armA, combined with phenotypic testing to guide empirical therapy and strengthen local surveillance of high-risk A. baumannii clones in hospital settings.